1. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW, He J. Report of cancer epidemiology in China, 2015. Zhonghua zhong liu za zhi [Chin J Oncol]. 2019;41(1):19–28.
2. Wang L, Zhang Y, Shi JF, Dai M. Disease burden of female breast cancer in China. Zhonghua liu xing bing xue za zhi Zhonghua liuxingbingxue zazhi. 2016;37(7):970–6.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.
4. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972–7.
5. Wang BY, Ge R, Jiang ZF. Breast Cancer Expert Group of Chinese Society of Clinical O: [Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer]. Zhonghua zhong liu za zhi [Chin J Oncol]. 2020;42(10):798–806.